Tokyo, Oct. 22 (Jiji Press)–A Fujifilm Holdings Corp. <4901> subsidiary said Thursday that it aims to sell its influenza drug Avigan, a candidate drug to treat the new coronavirus, in China.
Fujifilm Toyama Chemical Co. has selected Chinese drugmaker Carelink Pharmaceutical Co. as its partner in the Chinese market, as part of efforts to expand its overseas operations.
Fujifilm Toyama Chemical will provide Carelink with clinical data needed for the partner to import the drug. Carelink will apply for approval from Chinese authorities.
The two companies will also work together to develop an injectable form of Avigan, currently available in tablet form, so the drug can be used more widely.
In June, Fujifilm Toyama Chemical concluded licensing contracts with a major Indian drugmaker and a medical goods seller in the United Arab Emirates, allowing them to make and sell Avigan overseas. But China and Russia were not covered by the contracts.
Avigan, developed by Fujifilm Toyama Chemical, was approved in Japan as a drug for new types of influenza.
Last Friday, the company applied to the Japanese health ministry for approval of Avigan as a COVID-19 drug.